Trial Profile
Gastric acid suppression with PN400, a single-tablet, multilayer, fixed-dose formulation combining an immediate-relese Esomeprazole layer and enteric-coated naproxen core.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2010
Price :
$35
*
At a glance
- Drugs Esomeprazole/naproxen (Primary) ; Esomeprazole; Naproxen
- Indications Ankylosing spondylitis; Arthritis; Musculoskeletal pain; NSAID-induced gastrointestinal damage; Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
- 26 Sep 2009 New trial record.